TY - JOUR
T1 - Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to Cephalosporins and aztreonam by the revised CLSI breakpoints
AU - McWilliams, Carla S.
AU - Condon, Susan
AU - Schwartz, Rebecca M.
AU - Ginocchio, Christine C.
PY - 2014/7
Y1 - 2014/7
N2 - The incidence of aztreonam and cephalosporin susceptibility, determined using the revised CLSI breakpoints, for extendedspectrum-β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates was evaluated. Our analysis showed that results for aztreonam and/or ≥ 1 cephalosporin were reported as susceptible or intermediate for 89.2% of ESBLproducing E coli isolates (569/638 isolates) and 67.7% of ESBL-producing K. pneumoniae isolates (155/229 isolates).
AB - The incidence of aztreonam and cephalosporin susceptibility, determined using the revised CLSI breakpoints, for extendedspectrum-β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates was evaluated. Our analysis showed that results for aztreonam and/or ≥ 1 cephalosporin were reported as susceptible or intermediate for 89.2% of ESBLproducing E coli isolates (569/638 isolates) and 67.7% of ESBL-producing K. pneumoniae isolates (155/229 isolates).
UR - http://www.scopus.com/inward/record.url?scp=84903795633&partnerID=8YFLogxK
U2 - 10.1128/JCM.03613-13
DO - 10.1128/JCM.03613-13
M3 - Article
C2 - 24789185
AN - SCOPUS:84903795633
SN - 0095-1137
VL - 52
SP - 2653
EP - 2655
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
IS - 7
ER -